Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price shot up 1.6% during mid-day trading on Tuesday . The company traded as high as $97.1150 and last traded at $94.11. 1,705,128 shares were traded during mid-day trading, an increase of 801% from the average session volume of 189,291 shares. The stock had previously closed at $92.60.
Gemini Therapeutics Price Performance
The company has a 50 day simple moving average of $77.98 and a 200-day simple moving average of $63.12. The stock has a market capitalization of $4.08 billion, a P/E ratio of -94.11 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
See Also
- Five stocks we like better than Gemini Therapeutics
- How to Evaluate a Stock Before Buying
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- How to Read Stock Charts for Beginners
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
- CD Calculator: Certificate of Deposit Calculator
- Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
